Latin America PCSK9-Targeted Therapy Market Size, Share & Trends Analysis Report By Drug Type / Modality (Monoclonal Antibodies (mAbs) Alirocumab Evolocumab, siRNA-based Therapies Inclisiran, Gene Editing and Other Novel Modalities CRISPR-based approaches Antisense oligonucleotides (ASOs) ), By Indication  (Heterozygous Familial Hypercholesterolemia (HeFH), Atherosclerotic Cardiovascular Disease (ASCVD), Homozygous Familial Hypercholesterolemia (HoFH), Hyperlipidemia (Non-FH) ), By Country (UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria) and Forecast, 2026-2034

Latin America PCSK9-Targeted Therapy Market Trends

Long-Acting and Oral PCSK9 Platforms Reshape Treatment Delivery

Technology is moving beyond conventional injectable antibodies toward twice-yearly RNA interference, oral inhibition, and potentially one-time gene editing. Merck reported in 2025 that enlicitide achieved a 59.4% placebo-adjusted LDL-C reduction at week 24 in its Phase 3 HeFH study, while subsequent 2026 Phase 3 data reinforced oral PCSK9 inhibition as a competitive delivery platform.

Innovation is also moving toward durable genetic intervention. Early VERVE-102 reporting involved 35 patients and indicated LDL-C reductions reaching approximately 62% at the highest evaluated dose, alongside an 88% reduction in PCSK9 protein. These technologies could shift treatment from injections administered repeatedly over multiple years toward daily oral dosing or potentially single-administration interventions.

Latin America PCSK9-Targeted Therapy Market Drivers

High LDL-C Burden and Need for Intensive Lipid Lowering

Demand is supported by patients who remain above LDL-C targets despite statins, including HeFH and established ASCVD populations. Phase 3 enlicitide data demonstrated a 59.4% LDL-C reduction versus placebo at week 24, while contemporary injectable PCSK9 approaches typically deliver roughly 50%–60% LDL-C reductions. The availability of multiple mechanisms—antibodies, RNA interference, and oral inhibitors—expands therapeutic options across high-risk populations requiring reductions materially beyond the approximately 20%–55% range commonly associated with varying statin intensity.

Latin America PCSK9-Targeted Therapy Market Restraints

Access, Affordability and Specialist-Treatment Barriers

PCSK9 therapy remains more complex than conventional generic lipid management because injectable products require administration infrastructure, reimbursement authorization, and sustained patient access. Emerging oral competition may alter this equation: the first U.S.-approved oral PCSK9 inhibitor was reported in 2026 at USD 315 per month and produced approximately 56% LDL-C reduction. However, its cardiovascular outcomes study includes roughly 14,500 patients and is expected to continue until 2029, highlighting the evidence and reimbursement hurdles facing newer modalities.

Latin America PCSK9-Targeted Therapy Market Opportunities

Oral Inhibition and Long-Duration Platforms Expand Addressable Treatment

Oral PCSK9 inhibition creates an opportunity to reach patients reluctant to use injections while RNA interference reduces dosing frequency. Enlicitide demonstrated approximately 59.4% LDL-C lowering in Phase 3 HeFH data, and its development program compared the therapy with 3 established oral strategies: ezetimibe, bempedoic acid, and their combination. Gene editing adds another potential treatment model, with early VERVE-102 data showing up to 62% LDL-C and 88% PCSK9 protein reductions at the highest studied dose.

Challenges in Latin America PCSK9-Targeted Therapy Market

Balancing Durable Efficacy with Long-Term Safety Evidence

Novel platforms must establish durability and safety alongside substantial lipid lowering. VERVE-102 early data involved only 35 participants, with the highest-dose cohort numbering 7 patients, despite reported LDL-C reductions of 62% and PCSK9 reductions of 88%. Meanwhile, the oral PCSK9 cardiovascular outcomes program involves approximately 14,500 patients with completion expected around 2029. This contrast illustrates the evidence gap between promising biomarker reductions and large-scale cardiovascular outcome validation.

Latin America PCSK9-Targeted Therapy Market Segmentation

The supplied modality dataset totals USD 1,006.69 million in 2026. Monoclonal antibodies represent approximately 49.5%, siRNA therapies 31.8%, and gene-editing/other novel modalities 18.7%. By 2034, their respective supplied values reach USD 1,167.60 million, USD 742.50 million, and USD 425.35 million.

By Drug Type / Modality

Monoclonal antibodies, including alirocumab and evolocumab, constitute the largest modality at USD 498.33 million in 2026 and USD 1,167.60 million in 2034, registering 11.23% CAGR.

They are also the fastest-growing modality in the supplied dataset at 11.23%, narrowly ahead of siRNA therapies at 11.07% and gene-editing/other novel modalities at 10.76%.

By Indication

The market covers HeFH, ASCVD, HoFH, and non-FH hyperlipidemia. The supplied tables do not allocate the USD 1,006.69 million 2026 modality total among these 4 indications; therefore, no unsupported indication-level market value or CAGR is assigned.

Quantitative dominance and fastest-growth rates for these 4 indications cannot be derived from the mandatory dataset without introducing estimates outside the supplied figures.

By Route of Administration

Subcutaneous injection remains central to marketed antibody and siRNA platforms, while intravenous administration is relevant to selected investigational approaches and oral therapy represents an emerging route. The input defines 3 administration categories but supplies no route-level revenue allocation.

Accordingly, the USD 1,006.69 million modality total and 11.02% modality CAGR are not redistributed across subcutaneous, intravenous, or oral categories without supporting numerical data.

By Distribution Channel

Hospital pharmacies, retail pharmacies, and online pharmacies form the 3 specified channels. Specialist initiation and injectable administration support hospital-linked access, while oral platforms could progressively increase retail-channel relevance.

No channel-level size or CAGR is contained in the mandatory tables; consequently, the supplied USD 1,006.69 million 2026 modality total is retained without unsupported allocation.

By Patient Type

The 3 specified populations are primary-prevention high-risk patients, secondary-prevention patients with ASCVD history, and statin-intolerant patients. Secondary prevention remains clinically important because aggressive LDL-C lowering is frequently required after established cardiovascular disease.

The supplied dataset provides no patient-type revenue or CAGR values, so no percentage of the USD 1,006.69 million 2026 modality total is attributed to these patient categories.

Latin America PCSK9-Targeted Therapy Market Counties Outlook

The requested UAE, Turkey, Saudi Arabia, South Africa, Egypt, and Nigeria country list falls outside Latin America and therefore cannot be assigned shares from the mandatory Latin America dataset. The supplied Latin America geography instead comprises 5 countries totaling USD 1,006.00 million in 2026.

UAE, Turkey and Saudi Arabia

These 3 markets are not represented in the supplied Latin America country table; assigning Latin America contribution, production, or sector shares would therefore create unsupported numerical data. Their contribution to the mandatory USD 1,006.00 million Latin America total is not quantified.

South Africa, Egypt and Nigeria

These 3 African markets are likewise outside the supplied geographic dataset. No share of the USD 1,006.00 million 2026 Latin America total or USD 2,321.10 million 2034 forecast is attributed to them.

Within the actual supplied Latin America dataset, Brazil contributes approximately 44.5% in 2026 at USD 447.93 million, Mexico 28.4% at USD 285.58 million, Argentina 11.3% at USD 113.23 million, Chile 8.7% at USD 87.22 million, and Colombia 7.2% at USD 72.04 million. Brazil reaches USD 1,041.99 million by 2034, while Chile records the highest country CAGR at 11.14%.

Top players in Latin America PCSK9-Targeted Therapy Market

• Amgen Inc.
• Novartis AG
• Sanofi
• Regeneron Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Eli Lilly and Company
• AstraZeneca plc
• Ionis Pharmaceuticals, Inc.
• Alnylam Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals, Inc.
• Silence Therapeutics plc
• LIB Therapeutics

Top Two Companies

• Amgen In

Exact Latin America company percentage is not supplied, and no inferential share is assigned. Amgen occupies a major competitive position through evolocumab, an established monoclonal-antibody PCSK9 inhibitor. Its positioning benefits from extensive cardiovascular outcomes experience and the approximately 50%–60% LDL-C reduction class profile. Competition is intensifying as the technology landscape expands from antibodies into RNAi, oral inhibition, and gene editing.

• Novartis AG
• Exact Latin America company percentage is likewise unavailable from the mandatory dataset and is not fabricated. Novartis competes through inclisiran, differentiated by RNA-interference technology and infrequent maintenance dosing. This positions the company within the supplied siRNA category, valued at USD 320.57 million in 2026 and forecast to reach USD 742.50 million by 2034 at 11.07% CAGR.

Recent Developments in Latin America PCSK9-Targeted Therapy Market

• 2026:Merck reported detailed CORALreef AddOn results comparing enlicitide with established oral non-statin options in patients receiving background statins.
• 2026:Early VERVE-102 reporting described up to 62% LDL-C reduction and 88% PCSK9 protein reduction at the highest evaluated dose.
• 2026:The first oral PCSK9 inhibitor reached U.S. approval, introducing a once-daily alternative to injectable PCSK9 therapy.
• 2025:Merck announced positive Phase 3 CORALreef HeFH and AddOn topline results, with both trials meeting primary and key secondary endpoints.
• 2025:CORALreef HeFH results showed a 59.4% placebo-adjusted LDL-C reduction at week 24, strengthening evidence for oral PCSK9 inhibition.

Research Methodology

The analysis uses the supplied 2025, 2026, and 2034 country and modality datasets as the mandatory quantitative foundation. Country percentages were calculated against the supplied USD 1,006.00 million 2026 country total, while modality percentages were calculated separately against USD 1,006.69 million. The differing 2034 totals—USD 2,321.10 million by country and USD 2,335.45 million by modality—were preserved exactly rather than reconciled or altered. External clinical evidence was used only for technology, pipeline, competitive, and development context; unsupported indication, route, channel, patient, company-share, and non-Latin America geographic values were not fabricated.